Cargando…
Folate receptor targeted nanoparticles containing niraparib and doxorubicin as a potential candidate for the treatment of high grade serous ovarian cancer
Combination chemotherapy is an established approach used to manage toxicities while eliciting an enhanced therapeutic response. Delivery of drug combinations at specific molar ratios has been considered a means to achieve synergistic effects resulting in improvements in efficacy while minimizing dos...
Autores principales: | Wang, Lucy, Evans, James C., Ahmed, Lubabah, Allen, Christine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958112/ https://www.ncbi.nlm.nih.gov/pubmed/36828860 http://dx.doi.org/10.1038/s41598-023-28424-3 |
Ejemplares similares
-
Niraparib for ovarian cancer
Publicado: (2021) -
Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019) -
Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer
por: Shen, Yen Ting, et al.
Publicado: (2019) -
Niraparib in ovarian cancer: results to date and clinical potential
por: Caruso, Davide, et al.
Publicado: (2017) -
Identification of candidate genes associated with tubal origin of high-grade serous ovarian cancer
por: Xiang, Li, et al.
Publicado: (2018)